Literature DB >> 15142382

Effect of HIV-1 Vpr on cell cycle regulators.

Shohreh Amini1, Kamel Khalili, Bassel E Sawaya.   

Abstract

Cell cycle is one of the most complex processes in the life of a dividing cell. It involves numerous regulatory proteins, which direct the cell through a specific sequence of events for the production of two daughter cells. Cyclin-dependent kinases (cdks), which complex with the cyclin proteins, are the main players in the cell cycle. They can regulate the progression of the cells through different stages regulated by several proteins including p53, p21(WAF1), p19, p16, and cdc25. Downstream targets of cyclin-cdk complexes include pRB and E2F. A cell cycle can be altered to the advantage of many viral agents, most notably polyomaviruses, papillomaviruses, adenoviruses, and retroviruses. In addition, viral protein R (Vpr) is a protein encoded by the human immunodeficiency virus type 1 (HIV-1). HIV-1, the causative agent of acquired immunodeficiency syndrome (AIDS), is a member of the lentivirus class of retroviruses. This accessory protein plays an important role in the regulation of the cell cycle by causing G(2) arrest and affecting cell cycle regulators. Vpr prevents infected cells from proliferating, and collaborates with the matrix protein (MA) to enable HIV-1 to enter the nucleus of nondividing cells. Studies from different labs including ours showed that Vpr affects the functions of cell cycle proteins, including p53 and p21(WAF1). Thus, the replication of HIV-1, and ultimately its pathogenesis, are intrinsically tied to cell-cycle control.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142382     DOI: 10.1089/104454904773819833

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  28 in total

Review 1.  The rising challenge of non-AIDS-defining cancers in HIV-infected patients.

Authors:  John F Deeken; Angelique Tjen-A-Looi; Michelle A Rudek; Catherine Okuliar; Mary Young; Richard F Little; Bruce J Dezube
Journal:  Clin Infect Dis       Date:  2012-07-09       Impact factor: 9.079

Review 2.  Lung cancer in HIV-infected patients in the combination antiretroviral treatment era.

Authors:  José Moltó; Teresa Moran; Guillem Sirera; Bonaventura Clotet
Journal:  Transl Lung Cancer Res       Date:  2015-12

3.  Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Authors:  Sebastien Wurtzer; Séverine Compain; Henri Benech; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Proteolytic cleavage of HIV-1 GFP-Vpr fusions at novel sites within virions and living cells: concerns for intracellular trafficking studies.

Authors:  Leon Caly; David A Jans; Sabine C Piller
Journal:  J Fluoresc       Date:  2008-12-07       Impact factor: 2.217

Review 5.  Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.

Authors:  Paul G Rubinstein; David M Aboulafia; Andrew Zloza
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

6.  Retinoblastoma protein induction by HIV viremia or CCR5 in monocytes exposed to HIV-1 mediates protection from activation-induced apoptosis: ex vivo and in vitro study.

Authors:  Bethsebah Gekonge; Andrea D Raymond; Xiangfan Yin; Jay Kostman; Karam Mounzer; Ronald G Collman; Louise Showe; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2012-06-13       Impact factor: 4.962

Review 7.  Role of p53 in neurodegenerative diseases.

Authors:  J Robert Chang; Mohammad Ghafouri; Ruma Mukerjee; Asen Bagashev; Tinatin Chabrashvili; Bassel E Sawaya
Journal:  Neurodegener Dis       Date:  2011-10-28       Impact factor: 2.977

Review 8.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

9.  Pathway analysis for RNA-Seq data using a score-based approach.

Authors:  Yi-Hui Zhou
Journal:  Biometrics       Date:  2015-08-10       Impact factor: 2.571

10.  Human immunodeficiency virus infection inhibits granulocyte-macrophage colony-stimulating factor-induced microglial proliferation.

Authors:  Melissa Cosenza-Nashat; Meng-Liang Zhao; Heather D Marshall; Qiusheng Si; Susan Morgello; Sunhee C Lee
Journal:  J Neurovirol       Date:  2007-12       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.